EU/3/05/317

Table of contents

About

On 26 August 2005, orphan designation (EU/3/05/317) was granted by the European Commission to Henogen SA, Belgium, for a mixture of anti-CD3 mAb (SPV-T3a)-ricin A chain fusion protein and anti-CD7 mAb (WT1)-ricin A chain fusion protein for the treatment of graft-versus-host-disease.

The sponsorship was transferred to Xenikos BV, The Netherlands, in January 2010.

Key facts

Active substance
A mixture of anti-CD3 mAb (SPV-T3a)-ricin A chain fusion protein and anti-CD7 mAb (WT1)-ricin A chain fusion protein
Disease / condition
Treatment of graft-versus-host disease
Date of decision
26/08/2005
Outcome
Positive
Orphan decision number
EU/3/05/317

Sponsor's contact details

Xenikos BV
Molenveldlaan 168
6523RN Nijmegen
The Netherlands
Tel. +31 2430 00100
Fax +31 8474 10735
E-mail: y.vanoosterhout@xenikos.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating